H1-antihistamines for the treatment of anaphylaxis with and without shock
Country of origin: USA
Click for Full Details: www.mrw.interscience.wiley.comAnaphylaxis is a rare, but potentially life-threatening emergency. Evidence suggests that incidence may be increasing rapidly. Common triggers of anaphylaxis include a variety of foods, drugs and insect venoms.
H1-antihistamines are commonly used for the emergency treatment of anaphylaxis although the evidence underpinning this treatment is unclear. A systematic review of the literature has been conducted, searching key databases for high quality published and unpublished material on this subject; in addition, experts in this area and relevant pharmaceutical companies were contacted.
The searches failed to retrieve any randomised controlled trials on this subject. The review concludes there is no evidence from randomised controlled trials to support the use of H1-antihistamines in the emergency management of anaphylaxis.
The Cochrane review is available online.
Click for Full Details: www.mrw.interscience.wiley.com
Cancer.net mobile by ASCO January 2018
Infectious Disease Advisor January 2018
Clinical Pain Advisor January 2018
Cancer Emergency Response Tool - CERT January 2018
The Drugs & Bugs app January 2018
Managing Head Injury January 2018
Safety Report Gives Insight Into Patient Deterioration November 2017
Planning For The Management Of Burn-Injured Patients October 2017